Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Trading Up 3.2 %

Shares of ADXS stock opened at $0.28 on Tuesday. The company has a market capitalization of $3.05 million, a P/E ratio of -0.04 and a beta of 1.45. Ayala Pharmaceuticals has a 12 month low of $0.14 and a 12 month high of $1.95. The stock has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.61.

Ayala Pharmaceuticals (NASDAQ:ADXSGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.

Ayala Pharmaceuticals Company Profile

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Read More

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.